Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)-
rechallenged therapy for EGFR-mutant non-small cell lung cancer (NSCLC) patients who …

Introduction Anti-EGFR agents are standard treatments for patients with EGFR-mutant
advanced NSCLC. The feasibility of combining erlotinib or gefitinib with the anti …

PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …

Introduction EGFR exon 20 insertions comprise 4% to 9% of EGFR mutated NSCLC. Despite
being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine …

Introduction To evaluate the efficacy and safety of osimertinib plus bevacizumab for
previously untreated patients with advanced nonsquamous NSCLC harboring EGFR …

Background In the first interim analysis of the ORIENT-31 trial, compared with chemotherapy
alone, sintilimab plus bevacizumab biosimilar IBI305 plus chemotherapy (pemetrexed and …

Introduction Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI).
Durvalumab is an anti–programmed death ligand 1 monoclonal antibody. The phase III …

Abstract Introduction Almonertinib (HS-10296) is a novel, third-generation EGFR tyrosine
kinase inhibitor (EGFR TKI) that targets both EGFR-sensitizing and T790M resistance …

Background Osimertinib (AZD9291) is a potent, irreversible EGFR-TKI selective for EGFR-
TKI-sensitising (EGFRm) and T790M resistance mutations. We present updated efficacy and …